Latest News

Q4 2022 Watch: HHS renewed opioid emergency; CANN launched monkeypox project; HEPLISAV-B hepatitis B vaccine covered.

Q3 2022 review of HCV drug access across ADAPs, Medicaid, and comprehensive harm reduction programs.

ADAP Advocacy Association Fireside Chats resume with discussions on utilization management and EHE progress.

Q2 2022 Watch reviewing HCV treatment access across ADAPs, Medicaid, Veterans benefits, and assistance programs.

Q1 2022 assessment of HCV treatment access in ADAPs and Medicaid with DAA coverage and harm reduction data.

CANN announces 2022 organizational changes including rebranding and launching the 340B Action Center.

New CANN leadership reflects on mentorship and maintaining advocacy legacy following Bill Arnold's passing.

Q4 2021 Watch covering HCV drug formulary updates, ADAP and Medicaid changes, and pandemic impact on care.

Payers restrict HCV treatment through utilization management; patient assistance programs fill the critical gap.

Q3 2021 quarterly review of HCV drug access across ADAPs and Medicaid with harm reduction program updates.

Study of 109,283 patients links HIV status and viral hepatitis coinfection to significantly increased liver cancer rates.

Broken advocacy pipeline lacks investment in leadership development, compensation, and mentorship.

UNAIDS report highlights HIV-HCV coinfection rates among people who inject drugs globally and in the US.

Quarterly update on HCV treatment coverage across ADAPs, Medicaid, Veterans programs, and patient assistance options.

Quarterly Watch covering HCV treatment access across ADAPs and Medicaid, harm reduction programs, and COVID-19 impact on care.